PANGENOMIC HEALTH Aktie

 

  Not for distribution to United States Newswire Services or for dissemination in the United States   Vancouver, British Columbia, December 29, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce a private placement offering (the "Offering") of up to 4,000,000 units of the Company (the “Units”) at a price of $0.50 per Unit for gross proceeds and settlement of outstanding indebtedness of up to $2,000,000 (the “Offering”).   Each Unit will consist of one (1) Class A Common share in the capital of the Company (each a "Common Share") and one (1) share purchase warrant (each a “Warrant”), with each Warrant being exercisable for one (1) additional Common Share (a "Warrant Share") at a price of $0.75 per Warrant Share for a period of two (2) years from the date of issuance, subject acceleration.   It is anticipated that the net proceeds of the Offering will be utilized for general working ca...

  Vancouver, British Columbia, Canada – TheNewswire - December 5, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces that its Board of Directors has granted stock options representing a total of 2,00,000 common shares to officers and directors of the Company and its subsidiaries.  These options were granted at an exercise price of $0.65, being the closing price on December 4, 2025, will vest in equal quarterly instalments over a one year period, and will expire on December 5, 2028.  All options were granted pursuant to the Company's Stock Option Plan.   About PanGenomic Health   PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and well...

  Vancouver, British Columbia, Canada, November 4, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL3) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Ayla BioScience, Inc., a company formed under the laws of Delaware, USA (“Ayla BioScience”) to enter into an exclusive distribution agreement and a share purchase agreement.   Headquartered in the United States, with operational presence in Colombia and Jamaica, Ayla BioScience is a vertically integrated biomanufacturing company focused on developing and commercializing advanced functional food, nutraceutical, and plant-based bioactive products. The company leverages proprietary solid-state fermentation and dehydration technologies that enhance efficiency and preserve the molecular integrity of bioactive compounds.   Ayla BioScience has developed a diversified portfolio of products and ingredients under its ZeoMycel™ and Zeophytoz™ br...

  Vancouver, British Columbia, Canada, October 20, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that it has launched a DNA testing program as part of its Nara.Care AI platform for personalized wellness.   Working with a leading developer of DNA testing technologies, the Company will market its Agenta branded DNA testing kits to health-conscious consumers in Canada as part of an initial roll-out campaign. The Company plans to expand marketing into the United States in early 2026.   “We believe consumers are looking for better information about their unique health situation to help guide their personal wellness plans”, said Maryam Marissen, President & CEO of PanGenomic Health. “The foundation of our NaraCare.AI platform is personalization, and there is no better baseline for that foundation than incorporating the unique genetic makeup of each individual.”   The Agenta DNA tests will deliver signific...

  Vancouver, British Columbia, Canada, October 7, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that it has expanded its engagement with Fairfax Partners Inc. (“Fairfax”) of Vancouver, BC for the provision of investor relations, communications infrastructure and marketing services. The original services agreement with Fairfax was announced by the Company on June 20, 2025.   The amended services agreement with Fairfax will remain in effect for a period of twelve (12) months commencing on October 6, 2025. In accordance with the terms and conditions of the services agreement and as consideration for the services provided by Fairfax, the Company has agreed to pay a monthly cash fee of $7,500, plus applicable taxes. In addition, the Company has agreed to allocate up to $400,000, at the Company's discretion, over a 12-month period to be spent by Fairfax in coordination with the Company towards digital marketing an...

  Vancouver, British Columbia, Canada, September 23, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap Health"), plans to establish its Health AI Centre operations in Hong Kong.   “Mindleap Health is developing a real-world evidence (“RWE”) platform for the Complementary & Alternative Medicine (“CAM”) market and key to this platform will be access to health datasets in Asia and AI models developed by researchers in Asia”, said Robert Nygren, Executive Chair of PanGenomic Health and President of its wholly-owned subsidiary Mindleap Health. “With the support of a strategic advisory firm based in Hong Kong, we will set up a Health AI Centre in the fourth quarter of this year that will include development, research and marketing resources to advance our Mindleap RWE platform for CAM.”   The Mindleap RWE platform will collect and...

  Vancouver, British Columbia, Canada – TheNewswire - September 9, 2025 – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap Health"), is developing a real-world evidence (“RWE”) platform for the Complementary & Alternative Medicine (“CAM”) market.   “With profound changes taking place in the U.S. Food and Drug Administration and National Institutes of Health by Robert F. Kennedy Jr., the Secretary of Health and Human Services1, we believe there is a significant opportunity to develop a global evidence-based platform that collects information about the efficacy of non-pharmaceutical approaches to health and wellness”, said Robert Nygren, Executive Chair of PanGenomic Health and newly-appointed President of its wholly-owned subsidiary Mindleap Health. “These changes in the U.S. now complement decades-long advocacy efforts by the World Health Organi...

  Vancouver, British Columbia, Canada – TheNewswire - August 26, 2025 – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce that it will attend and be a sponsor of the Vivacity trade conference, providing a strategic opportunity to showcase the Company's recently announced Agenta Health e-Commerce platform.   The Vivacity Medical Aesthetics & Healthy Aging Show will take place in Vancouver, BC from September 19-21, 2025, and will be held in the Vancouver Convention Centre.  The inaugural trade show is marketed as “The Consumer Marketplace Where Medical Aesthetics, Longevity and, Healthy Aging Meet”, and the conference anticipates over 20,000 attendees.   “The Vivacity trade event will be a unique opportunity to showcase our Agenta Health platform and our line of products that support a holistic approach to health and wellness”, said Maryam Marissen, President & CEO of PanGenomic Health. “Agenta Health is strongly aligned w...

  Vancouver, British Columbia, Canada – TheNewswire - August 19, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it has launched its new eCommerce shopping site, a key component of the NaraCare.AI platform strategy previously announced on July 25, 2025.   Agenta Health   “The Agenta Health eCommerce site is the springboard for our NaraCare.AI platform”, said Maryam Marissen, President & CEO of PanGenomic Health. “We believe consumers are missing personalized online shopping experiences for alternative health products and are looking for better information about products that fit their unique health situation, lifestyle and personal goals.”   The Agenta Health eCommerce shopping site provides consumers with a unique line of products to support a holistic approach to health and wellness. Evidence-based information about benefits, dosage use, adverse effects and drug interactions will be incorporated into the...

  Vancouver, British Columbia, Canada, July 25, 2025 – TheNewswire - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to provide a corporate update on recent strategic initiatives.   NaraCare.AI Platform Strategy   “PanGenomic Health is pleased to announce that it is developing a new AI health platform for personalized alternative health products”, said Maryam Marissen, President & CEO of PanGenomic Health. “Consumers and their health practitioners face challenges in understanding which alternative health products are right for the whole health of an individual, and we believe that our NaraCare.AI platform can become the trusted source for consumers and practitioners across North America.”   A holistic approach to health and wellness requires listening to what the mind and body are saying. The NaraCare.AI platform will leverage insights and functionality developed in our Nara mental health app, our Mindleap telehealth platform and o...

  Vancouver, British Columbia, Canada, July 11, 2025 – TheNewswire - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce the appointment of Manpreet Dhillon as a director of the Company. Ms. Dhillon has over 20 years of international consulting experience specializing in implementing programs on economic empowerment, gender equality, and stakeholder engagement for international non-governmental organizations and governments within the United Nations system. Ms. Dhillon is the founder of Veza Global, a Canadian organization working globally to provide solutions to support employers, human resource practitioners and organizations as a whole to effectively address diversity, equity, inclusion and belonging in the communities they serve. Ms. Dhillon has significant experience as a strategic leader with expertise in equity, diversity, and inclusion programs, strategic planning, stakeholder engagement, brand development and leadership coaching....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

  Vancouver, British Columbia, Canada – TheNewswire - July 2, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it has filed its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “2024 Year End Financial Statements”). The 2024 Year End Financial Statements, together with detailed information regarding the Company's financial results as set forth in the Company's Management's Discussion and Analysis, can be found under the Company's profile at www.sedarplus.ca.   About PanGenomic Health   PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society...

  Vancouver, British Columbia, Canada – TheNewswire - June 26, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), further to its news release of June 12, 2025 (the “Third MCTO Update”), provides an update with respect to the management cease trade order (the “MCTO”) dated May 1, 2025 issued by the British Columbia Securities Commission (the “BCSC”) in connection with the delay by the Company in filing its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “Financial Statements”) and the related management's discussion and analysis and CEO and CFO certificates for the same period (collectively, with the Financial Statements, the “Required Filings”) before the filing deadline of April 30, 2025 (the “Filing Deadline”).   The Company has been working closely with its auditors and expects to file the Required Filings on or before June 30, 2025.   The Company's inability to make ...

  Vancouver, British Columbia, Canada, June 20, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce that it has engaged the services of Fairfax Partners Inc. (“Fairfax”) of Vancouver, BC to provide investor relations, communications infrastructure and marketing services. The services agreement with Fairfax will remain in effect for a period of six (6) months commencing on June 20, 2025. In accordance with the terms and conditions of the services agreement and as consideration for the services provided by Fairfax, the Company has agreed to pay a monthly cash fee of $5,000, plus applicable taxes. Fairfax Partners Inc. is an unrelated third party service provider.  Fairfax Partners Inc., including its owners and directors, does not hold, directly or indirectly, any ownership or interest in the securities of the Company.   Acceleration of Warrant Expiration Date   The Company also provides an update regarding the acceleration ...

  Vancouver, British Columbia, Canada – TheNewswire - June 12, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), further to its news release of May 29, 2025 (the “Second MCTO Update”), provides an update with respect to the management cease trade order (the “MCTO”) dated May 1, 2025 issued by the British Columbia Securities Commission (the “BCSC”) in connection with the delay by the Company in filing its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “Financial Statements”) and the related management's discussion and analysis and CEO and CFO certificates for the same period (collectively, with the Financial Statements, the “Required Filings”) before the filing deadline of April 30, 2025 (the “Filing Deadline”).   The Company has been working closely with its auditors and expects to file the Required Filings on or before June 30, 2025.   The Company's inability to make ...

  Vancouver, British Columbia, Canada – TheNewswire - May 29, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), further to its news release of May 15, 2025 (the “First MCTO Update”), provides an update with respect to the management cease trade order (the “MCTO”) dated May 1, 2025 issued by the British Columbia Securities Commission (the “BCSC”) in connection with the delay by the Company in filing its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “Financial Statements”) and the related management's discussion and analysis and CEO and CFO certificates for the same period (collectively, with the Financial Statements, the “Required Filings”) before the filing deadline of April 30, 2025 (the “Filing Deadline”).   The Company has been working closely with its auditors and expects to file the Required Filings on or before June 30, 2025.   The Company's inability to make th...

  Vancouver, British Columbia, Canada, May 15, 2025 – TheNewswire - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), further to its news release of May 1, 2025 (the “MCTO Announcement”), provides an update with respect to the management cease trade order (the “MCTO”) dated May 1, 2025 issued by the British Columbia Securities Commission (the “BCSC”) in connection with the delay by the Company in filing its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “Financial Statements”) and the related management's discussion and analysis and CEO and CFO certificates for the same period (collectively, with the Financial Statements, the “Required Filings”) before the filing deadline of April 30, 2025 (the “Filing Deadline”).   The Company has been working closely with its auditors and expects to file the Required Filings on or before June 30, 2025.   The Company's inability to make the Re...

  Vancouver, British Columbia, Canada, May 1, 2025 – TheNewswire - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces that, further to its news release of April 12, 2025 (the “Default Announcement”), the British Columbia Securities Commission (the “BCSC”) has issued a management cease trade order (the “MCTO”) dated May 1, 2025 in connection with the delay by the Company in filing its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “Financial Statements”) and the related management's discussion and analysis and CEO and CFO certificates for the same period (collectively, with the Financial Statements, the “Required Filings”) before the filing deadline of April 30, 2025 (the “Filing Deadline”).   The Company has been working closely with its auditors and expects to file the Required Filings on or before June 30, 2025.   The Company's inability to make the Required Filings b...

  Vancouver, British Columbia, Canada – TheNewswire - April 11, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces that it has made an application to the British Columbia Securities Commission to approve a management cease trade order (“MCTO”) under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”), which, if granted, will prohibit the Chief Executive Officer and Chief Financial Officer of the Company from trading in securities of the Company until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company and the MCTO has been revoked. During the period in which the MCTO is effective, the general public will continue to be able to trade in the Company's listed securities. The MCTO application has been made but there is no guarantee or assurance that the MCTO will be granted.   The Company expects that it will be unable to fi...